N-methyl-2-pyrrolidone   Click here for help

GtoPdb Ligand ID: 9520

Abbreviated name: NMP
Synonyms: N-methyl-pyrrolidone
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: NMP is a common solvent and drug vehicle. More recently it has been identified as a candidate bromodomain ligand with antineoplastic and immunomodulatory activity [1]. Mechanistically it appears to be a low-affinity, broad-spectrum acetyllysine mimetic, but with apparent comparable ligand efficiency to that of larger rationally developed compounds such as (+)-JQ1 because of its very low molecular weight.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 0
Topological polar surface area 20.31
Molecular weight 99.07
XLogP -0.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C1CCCN1C
Isomeric SMILES O=C1CCCN1C
InChI InChI=1S/C5H9NO/c1-6-4-2-3-5(6)7/h2-4H2,1H3
InChI Key SECXISVLQFMRJM-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
NMP is being evaluated in Phase 1 clinical trial for safety and immunological and anti-tumour efficacy in patients with myeloma who are resistant to or intolerant of lenalidomide and bortezomib (NCT02468687).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02468687 NMP in Relapsed / Refractory Myeloma Phase 1 Interventional Peter MacCallum Cancer Centre, Australia